-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers from Northwestern University found that many cancers produce an enzyme called IDO (indoleamine 2,3-dioxygenase 1, indoleamine 2,3-dioxygenase 1).
In addition to participating in tryptophan metabolism, IDO can also enhance the immunosuppressive factors of the complement immune system
Many difficult-to-treat cancers, including glioblastoma, prostate cancer, and pancreatic cancer, show high levels of IDO expression
Many clinical trials that use drug-based IDO enzyme inhibitors in combination with immunotherapy have shown that there is no improvement in patient survival compared with immunotherapy alone
These authors found that IDO, regardless of its ability to metabolize tryptophan, is related to the decreased survival rate of experimental animals with brain tumors and increased accumulation of immunosuppressive cells
When they were studying the role of IDO in tumor cells, a special approach caught their attention: the complement cascade
Glioblastoma
Note: The original text has been deleted
Reference materials:
Lijie Zhai et al.
